Chronic hand eczema (CHE) is a distressing skin condition that affects millions of adults worldwide, causing discomfort, pain, and a significant impact on daily life. The recent FDA approval of Anzupgo (delgocitinib) cream marks a major milestone in the treatment of moderate-to-severe CHE, offering hope to those who have struggled with limited options and ineffective therapies.
Developed by LEO Pharma, this steroid-free topical cream targets the inflammatory processes behind CHE by blocking key components of the JAK-STAT signaling pathway. Clinical trials have demonstrated its effectiveness in managing symptoms and preventing flare-ups, providing much-needed relief for patients. With a clear focus on addressing unmet medical needs, Anzupgo represents a significant advancement in dermatological care, showcasing the power of innovation and research in improving the lives of individuals with chronic skin conditions.
Read more from managedhealthcareexecutive.com